hlx53
Recombinant proteinexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 15, 2022 (NCT05394168)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06349980 | Phase 2 | May 10, 2024 | Fudan University, Shanghai Henlius Biotech |
| NCT05394168 | Phase 1 | Sep 15, 2022 | Fudan University, Shanghai Henlius Biotech |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fudan University | Academic/Hospital | 2 | 0 | 2 | 2022 |
| Shanghai Henlius Biotech | For profit | 2 | 2 | 2 | 2022 |
2 organizations
Page 1 / 1